Research status of inhaler triple therapy for chronic obstructive pulmonary disease
10.13699/j.cnki.1001-6821.2017.21.029
- VernacularTitle:慢性阻塞性肺疾病三联用药定量吸入剂的研究现状
- Author:
Jing-Zi LI
1
;
Ying ZHOU
;
Yi-Min CUI
Author Information
1. 北京大学第一医院药剂科
- Keywords:
chronic obstructive pulmonary disease;
triple therapy;
inhaled corticosteroid/ long-acting β2-agonist /long-acting bronchodilators
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(21):2199-2201,2205
- CountryChina
- Language:Chinese
-
Abstract:
Chronic obstructive pulmonary disease (COPD)is a common chronic respiratory system disease that could not be cured,and the prevalence and cost of which is high.Triple inhaled therapy of inhaled corticosteroid/long-acting β2-agonist/long-acting bronchodilators (ICS/ LABA/LAMA) improves lung function,symptoms and health status and reduces exacerbations compared to ICS/LABA or LAMA monotherapy.Single-inhaler combination of ICS/LABA/LAMA can improve patient compliance and efficacy.However,it's hard to change the specific dose of one single compound through a single-inhaler combination of three compounds.This review aimed to provide information for the rational clinical use of the single inhaler of triple therapy in the future.
